(7 days)
Not Found
No
The device description and performance studies focus on the physical characteristics and biocompatibility of a disposable needle, with no mention of software, algorithms, or data processing that would indicate AI/ML.
No
This device is an insulin injection needle, which is used for the administration of a therapeutic product (insulin), but it is not a therapeutic device itself.
No
The device is described as an insulin injection delivery needle, designed for subcutaneous administration of insulin. It does not perform any diagnostic functions or analyze medical conditions.
No
The device description clearly describes a physical needle (NovoFine® 32G Tip needle) designed for use with insulin injection delivery devices. It details the physical process of attaching and using the needle, indicating it is a hardware component.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the subcutaneous administration of insulin. This is a therapeutic delivery function, not a diagnostic test performed on samples taken from the body.
- Device Description: The description details a needle used for injection, which is consistent with drug delivery, not in vitro testing.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), reagents, or any process related to diagnosing a condition based on in vitro analysis.
IVD devices are used to examine specimens from the human body to provide information for diagnosis, monitoring, or screening. This device is a delivery mechanism for a therapeutic product.
N/A
Intended Use / Indications for Use
NovoFine® 32G Tip needles are used in conjuction with insulin injection delivery devices for subcutaneous administration of sterile parenteral insulin products.
Product codes (comma separated list FDA assigned to the subject device)
FMI
Device Description
The NovoFine® 32G Tip needle is designed for single use in conjunction with insulin injection delivery devices. Prior to giving an injection, the protective tab is removed from the plastic needle cap of the single-use disposable needle. With the disposable needle remaining in the needle cap, it is then carefully screwed onto the delivery injection device until tight and then the needle outer and inner caps are removed. Prepare for injection by following the procedure described in the instruction leaflet provided with the pen injection device and instructions from your health care professional.
After the injection, the needle is removed from the skin. The needle is detached from the injection device and disposed of in accordance with local regulations. For each subsequent injection, another disposable needle must be used. Delivery device function checks can be performed with the NovoFine® 32G Tip by using the needle cap as described in the instruction leaflet provided with the pen injection device.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The NovoFine® 32G Tip needles will be manufactured in accordance with current Good Manufacturing Practices for Medical Devices. Biocompatibility and performance tests have been performed and the results are in compliance with existing domestic and international standards.
No clinical tests are required.
Based on the design equivalency and the functional testing, Novo Nordisk had determined that the NovoFine® 32G Tip needles are substantially equivalent to a device currently marketed in the United States. Differences between the devices do not raise any significant issues of safety and effectiveness.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 880.5570 Hypodermic single lumen needle.
(a)
Identification. A hypodermic single lumen needle is a device intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin. The device consists of a metal tube that is sharpened at one end and at the other end joined to a female connector (hub) designed to mate with a male connector (nozzle) of a piston syringe or an intravascular administration set.(b)
Classification. Class II (performance standards).
0
DEC 2 1 2005
NovoFine® 32G Tip Disposable Needle
510(k) Premarket Notification
Date: Version: Status:
10 Oct 2005 Novo Nordisk ﺴﻤ Final
Novo Nordisk Inc.
807.87(h) 510(k) Summary 10
As required by Section 807.92(a)
(1) DATE OF PREPARATION: December 2, 2005
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. NovoFine® 32G Tip needles meet all applicable product and quality standards for hypodermic single lumen needle products.
SUBMITTER'S NAME AND ADDRESS:
| Novo Nordisk Inc.
100 College Road West
Princeton, New Jersey 08540 | Contact Person: John Signorin
Tel: 609-987-5967
Fax: 609-987-3910 |
| --------------------------------------------------------------------------- | ------------------------------------------------------------------------- |
|---|
(2) NAME OF DEVICE:
| Proprietary Name: | NovoFine ® 32G Tip needles |
|---|---|
| Common or usual name: | Sterile disposable hypodermic needle |
| Classification: | Hypodermic single lumen needle |
| Class: | Class II |
(3) SUBSTANTIAL EQUIVALENCE:
The NovoFine® 32G Tip x 6 mm needle is substantially equivalent to the Novo Nordisk NovoFine * 31G x 6 mm needle (K002403) which was cleared by FDA in December 2000.
The term "substantial equivalence" as used in this 510(k) notification is limited to the definition of substantial equivalence as found in the Federal Food, Drug, and Cosmetic Act, as amended and as supplied under 21 CFR 807, Subpart E under which a device can be marketed without pre-market approval or reclassification. A determination of substantial equivalency under this notification is not intended to have any bearing whatsoever on the
1
| NovoFine 32G Tip
Disposable Needle | 510(k) Premarket Notification | Date: 10 Oct 2005
Version: 1
Status: Final Novo Nordisk |
| --------------------------------------- | ------------------------------- | --------------------------------------------------------------- |
|---|
Novo Nordisk Inc.
807.87(h) 510(k) Summary (continued)
resolution of patent infringement suits or any other patent matters. No statement related to, or in support of substantial equivalence herein shall be construed as an admission against interest under the US Patent laws or their application by the court.
(4) DEVICE DESCRIPTION:
The NovoFine® 32G Tip needle is designed for single use in conjunction with insulin injection delivery devices. Prior to giving an injection, the protective tab is removed from the plastic needle cap of the single-use disposable needle. With the disposable needle remaining in the needle cap, it is then carefully screwed onto the delivery injection device until tight and then the needle outer and inner caps are removed. Prepare for injection by following the procedure described in the instruction leaflet provided with the pen injection device and instructions from your health care professional.
After the injection, the needle is removed from the skin. The needle is detached from the injection device and disposed of in accordance with local regulations. For each subsequent injection, another disposable needle must be used. Delivery device function checks can be performed with the NovoFine® 32G Tip by using the needle cap as described in the instruction leaflet provided with the pen injection device.
(5) INTENDED USE:
The intended use for the modified device remains the same as the predicate device (NovoFine 31G):
For use in conjunction with insulin injection delivery devices for subcutaneous administration of sterile parenteral insulin products.
2
| NovoFine® 32G Tip
Disposable Needle | 510(k) Premarket Notification | Date:
Version:
Status: | Final | 10 Oct 2005 Novo Nordisk |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|------------------------------|-------|----------------------------|
| X I _ _ _ _ _ L _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ | | | | |
Novo Nordisk Inc.
807.87(h) 510(k) Summary (continued)
(6) TECHNOLOGICAL CHARACTERISTICS:
The NovoFine® 32G Tip needle is substantially equivalent to the NovoFine® 31G needle in intended use, technology/principle of operation, materials and performance. Differences between the devices do not raise any significant issues of safety and effectiveness.
Section 807.92(b)
(1) NON-CLINICAL TESTS PERFORMED:
The NovoFine® 32G Tip needles will be manufactured in accordance with current Good Manufacturing Practices for Medical Devices. Biocompatibility and performance tests have been performed and the results are in compliance with existing domestic and international standards.
(2) CLINICAL TESTS SUBMITTED:
No clinical tests are required.
(3) CONCLUSIONS DRAWN FROM THE NON-CLINICAL AND CLINICAL TESTS:
Based on the design equivalency and the functional testing, Novo Nordisk had determined that the NovoFine® 32G Tip needles are substantially equivalent to a device currently marketed in the United States. Differences between the devices do not raise any significant issues of safety and effectiveness.
Mell Me Elligson
Mary Ann McElligott, Associate Vice President, Regulatory Affairs Novo Nordisk Inc.
12/13/05
Date
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three curved lines.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
DEC 2 1 2005
Mr. John Signorin Manager, Regulatory Affairs Novo Nordisk, Incorporated 100 College Road West Princeton, New Jersey 08540
Re: K053470
Trade/Device Name: NovoFine® 32G Tip ¼" (6mm) Disposable Needle Regulation Number: 880.5570 Regulation Name: Hypodermic Single Lumen Needle Regulatory Class: II Product Code: FMI Dated: December 13, 2005 Received: December 14, 2005
Dear Mr. Signorin:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device mendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general approvisions of the Act. The general controls provisions of the Act include controls pro farman al registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting (1 Mr.), it may of backed to back of Federal Regulations, Title 21, Parts 800 to 898. In your device tax roublish further announcements concerning your device in the Lederal Register.
4
Page 2 - Mr. Signorin
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements moan that I Drima made a detes and regulations administered by other Federal agencies. or the For any I vith all the Act's requirements, including, but not limited to: registration r od into compry with and 807); labeling (21 CFR Part 801); good manufacturing practice and fisting (21 CF RT rar 007), acclity systems (QS) regulation (21 CFR Part 820); and if requirements as set form in are quadiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) I remarket notification. The FDA finding of substantial equivalence of your device to a premainer notification. For the results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), 11 you don't the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the may overnit our gamer gaternational and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Sydtte y. Michael Omd.
Chiu Lin, Ph.D. Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
5
NovoFinc® 32G Tip Disposable Needle
510(k) Premarket Notification
Date: Version Status:
administration of sterile parenteral insulin products.
10 Oct 2005 Novo Nordisk Final
Novo Nordisk Inc.
Indication for Use Statement 2
K053470 Not available 510(k) Number (if known) NovoFine® 32G Tip Device Name: ¼" (6 mm) Disposable needle NovoFine® 32G Tip needles are used in conjunction Indications For Use: with insulin injection delivery devices for subcutaneous
Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use
(21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
1 :: :: : : : : : : : : ... ku 53470 . . . . . . . .
Novo Nordisk Inc.